Cardiovascular Risk and Statin Use in the United States

被引:64
作者
Johansen, Michael Edward [1 ,2 ]
Green, Lee A. [2 ,3 ]
Sen, Ananda [2 ,4 ]
Kircher, Sheetal [5 ]
Richardson, Caroline R. [2 ,6 ,7 ]
机构
[1] Ohio State Univ, Dept Family Med, Columbus, OH 43201 USA
[2] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA
[3] Univ Alberta, Dept Family Med, Edmonton, AB T6G 2M7, Canada
[4] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[5] Northwestern Univ, Dept Internal Med Hematol Oncol, Evanston, IL USA
[6] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA
[7] VA Ctr Clin Management Res, Ann Arbor, MI USA
关键词
cardiovascular: coronary artery disease; cardiovascular: hyperlipidemia; endocrinology: diabetes; primary care issues; CORONARY-HEART-DISEASE; PRIMARY PREVENTION; LOWERING TREATMENT; CHOLESTEROL; THERAPY; PEOPLE; METAANALYSIS; MORTALITY; TRENDS; TRIALS;
D O I
10.1370/afm.1641
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE Statins reduce the risk of mortality and coronary artery disease in individuals at high cardiovascular risk. Using nationally representative data, we examined the relationships between statin use and cardiovascular risk, diagnosis of hyperlipidemia, and other risk factors. METHODS We analyzed data from the 2010 Medical Expenditure Panel Survey, a nationally representative survey of the US civilian noninstitutionalized population. The study sample had a total of 16,712 individuals aged 30 to 79 years. Those who reported filling at least 2 statin prescriptions were classified as statin users. We created multiple logistic regression models for statin use as the dependent variable, with cardiovascular risk factors and sociodemographic factors as independent variables. RESULTS Overall, 58.2% (95% CI, 54.6%-61.7%) of individuals with coronary artery disease and 52.0% (95% CI, 49.4%-54.6%) of individuals with diabetes aged older than 40 years were statin users. After adjusting for cardiovascular risk factors and sociodemographic factors, the probability of being on a statin was significantly higher among individuals with both hyperlipidemia and coronary artery disease, at 0.44 (95% CI, 0.40-0.48), or hyperlipidemia only, at 0.32 (95% CI, 0.30-0.33), than among those with coronary artery disease only, at 0.11 (95% CI, 0.07-0.15). A similar pattern was seen in people with diabetes. CONCLUSIONS In this nationally representative sample, many people at high risk for cardiovascular events, including those with coronary artery disease, diabetes, or both, were not receiving statins despite evidence that these agents reduce adverse events. This undertreatment appears to be related to placing too much emphasis on hyperlipidemia and not enough on cardiovascular risk. Recently released guidelines from the American College of Cardiology and the American Heart Association offer an opportunity to improve statin use by focusing on cardiovascular risk instead of lipid levels.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 34 条
[1]   Statin Use in Outpatients With Obstructive Coronary Artery Disease [J].
Arnold, Suzanne V. ;
Spertus, John A. ;
Tang, Fengming ;
Krumholz, Harlan M. ;
Borden, William B. ;
Farmer, Steven A. ;
Ting, Henry H. ;
Chan, Paul S. .
CIRCULATION, 2011, 124 (22) :2405-+
[2]   Lipid-lowering for peripheral arterial disease of the lower limb [J].
Aung, P. P. ;
Maxwell, H. G. ;
Jepson, R. G. ;
Price, J. F. ;
Leng, G. C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (04)
[3]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[4]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[5]  
Collins R, 2003, LANCET, V361, P2005
[6]   Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: An analysis of patient data from a Maryland-based health maintenance organization [J].
Cooke, Catherine E. ;
Hammerash, William J., Jr. .
CLINICAL THERAPEUTICS, 2006, 28 (04) :591-599
[7]  
EDWARDS WS, 1994, VITAL HLTH STAT, V2, P94
[8]   Quality of care for secondary prevention for patients with coronary heart disease: Results of the Hastening the Effective Application of Research through Technology (HEART) trial [J].
Goff, DC ;
Gu, L ;
Cantley, LK ;
Sheedy, DJ ;
Cohen, SJ .
AMERICAN HEART JOURNAL, 2003, 146 (06) :1045-1051
[9]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[10]   Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem [J].
Hayward, Rodney A. ;
Hofer, Timothy P. ;
Vijan, Sandeep .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (07) :520-530